A new study has found that SGLT-2 inhibitor drugs for type 2 diabetes may also reduce the risk of kidney stones and gout. These painful conditions are ...
SGLT2 inhibitors may help reduce the risk of nephrolithiasis in patients with type 2 diabetes, including those with co-existing gout. Recent large-scale studies support that sodium-glucose ...
Gout causes sudden flares of joint pain, which often arise during the nighttime, and in the big toe, though it may affect other joints including the ankles | Genetics And Genomics ...
It is estimated that more than 5.6 million people in the UK are living with diabetes, with 90 per cent suffering from type 2 ...
For patients with nephrolithiasis, sodium-glucose cotransporter-2 (SGLT-2) inhibitor use is associated with a reducti ...
The FDA has just dropped a truth bomb: if you’ve been relying on those familiar red pills for a stuffy nose, it might be time ...
In the complex landscape of reproductive health, emergency contraception stands as a critical option for individuals seeking ...
Amgen today announced the presentation of new data across its rare disease portfolio and pipeline at the annual American College of Rheumatology (ACR) Convergence 2024 conference in Washington, D.C., ...
Gout affects around one in 40 people in developed ... while others are intolerant to the drugs. Sobi’s filing is based on the DISSOLVE I and II pivotal studies, in which roughly half of the ...